BostonGene’s Multiomic AI Platform Uncovers Therapeutic Targets in Invasive Lobular Carcinoma, Wins GRASP Advocate Choice Award at ASCO 2025
Study Identifies Disease-Specific Targets to Inform Precision Drug Development in Breast Cancer
Excerpt from the Press Release:
WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster, titled “Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes,” was presented by Jason Mouabbi, MD, of The University of Texas MD Anderson Cancer Center, on June 2, 2025.
In collaboration with MD Anderson, BostonGene applied its proprietary multiomic AI platform to profiles of over 600 patients, uncovering distinct histologic and molecular features of invasive lobular carcinoma (ILC)—a breast cancer subtype for which treatment decisions are often inferred from other subtypes. The study revealed previously under-characterized macroscale genomic alterations and biologic mechanisms, highlighting opportunities for precision-targeted therapies and novel drug development strategies tailored to ILC. These insights demonstrate BostonGene’s unique capabilities to uncover disease-specific targets and enable data-driven decisions in clinical development.
The GRASP (Guiding Researchers and Advocates to Scientific Partnerships) Advocate Choice Award recognizes research that is both scientifically meaningful and impactful to the patient community, as determined by cancer advocates. GRASP is a nonprofit, patient-led initiative that brings together researchers, clinicians and patients to foster scientific collaboration and accelerate innovation in cancer care.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?